Trabectedin–olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group
Although trabectedin-olaparib combination reached the prespecified threshold for statistical significance for PFS (P < 0.10), the benefit was marginal in the all-comers STS population. Nonetheless, patients affected by PARP1-expressing STS and uterine leiomyosarcoma derived substantial benefit from the combination, supporting further histology- and biomarker-driven investigation in these settings.
Authors
- Sara E. Bellomo (ORCID: https://orcid.org/0000-0001-5738-2351)
- Anna Paioli (ORCID: https://orcid.org/0000-0002-8587-7893)
- Martina Rabino (ORCID: https://orcid.org/0000-0003-1416-931X)
- Enrico Berrino (ORCID: https://orcid.org/0000-0001-6728-5619)
- Angelo Paolo Dei Tos (ORCID: https://orcid.org/0000-0002-1228-8940)
- Alessandra Merlini (ORCID: https://orcid.org/0000-0002-5280-1411)
- Maria Abbondanza Pantaleo (ORCID: https://orcid.org/0000-0002-0177-6957)
- Virginia Ferraresi (ORCID: https://orcid.org/0000-0001-6419-1668)
- L. Righi
- Dario Sangiolo (ORCID: https://orcid.org/0000-0002-7163-7071)
- Tommaso Martino De Pas
- Giovanni Grignani (ORCID: https://orcid.org/0000-0001-5515-569X)
- Ymera Pignochino (ORCID: https://orcid.org/0000-0001-5073-8618)
- Francesco Tolomeo (ORCID: https://orcid.org/0000-0003-3595-8238)
- Giuseppe Badalamenti (ORCID: https://orcid.org/0000-0002-2478-8838)
- Angela Buonadonna (ORCID: https://orcid.org/0000-0002-1930-0308)
- Roberta Sanfilippo (ORCID: https://orcid.org/0000-0002-9704-0521)
- Silvia Stacchiotti (ORCID: https://orcid.org/0000-0002-1742-8666)
- Giacomo Giulio Baldi (ORCID: https://orcid.org/0000-0003-0798-7752)
- Caterina Marchiò (ORCID: https://orcid.org/0000-0003-2024-6131)
- Lorenzo D’Ambrosio (ORCID: https://orcid.org/0000-0003-3294-8819)
- Marta Sbaraglia (ORCID: https://orcid.org/0000-0002-7116-6513)
- Bruno Vincenzi (ORCID: https://orcid.org/0000-0001-8222-9025)
- S. Aliberti (ORCID: https://orcid.org/0000-0001-6990-9341)
- Lorena Gurrieri (ORCID: https://orcid.org/0000-0001-8935-8794)
- Antonella Brunello (ORCID: https://orcid.org/0000-0003-2583-5226)
Institutions
- University of Padua (IT)
- Università Campus Bio-Medico (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Istituto Oncologico Veneto (IT)
- Azienda USL di Bologna (IT)
- Istituto Ortopedico Rizzoli (IT)
- Humanitas Gavazzeni (IT)
- Centro di Riferimento Oncologico (IT)
- National Cancer Institute (MY)
- Campus Bio Medico University Hospital (IT)
- Azienda Ospedale - Università Padova (IT)
- Candiolo Cancer Institute (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Ospedale San Luigi Gonzaga (IT)
- Azienda Usl Toscana Centro (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Hospital of Prato (IT)
- University of Palermo (IT)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1016/j.annonc.2025.11.019
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro
- PharmaMar